Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial

      Background

      Biologic therapies with anti–tumor necrosis factor agents are promising treatments for hidradenitis suppurativa (HS).

      Objective

      We assessed the efficacy and safety of infliximab (IFX) for the treatment of moderate to severe HS.

      Methods

      A prospective double-blind treatment phase of 8 weeks where patients received IFX or placebo was followed by an open-label phase where patients taking placebo were given the opportunity to cross over to IFX, and an observational phase. Primary treatment efficacy was based on HS Severity Index. Secondary end points included Dermatology Life Quality Index, visual analog scale, and Physician Global Assessment scores. Inflammatory markers erythrocyte sedimentation rate and C-reactive protein were also assessed.

      Results

      More patients in the IFX than in the placebo group showed a 50% or greater decrease from baseline HS Severity Index score. In addition, statistically and clinically significant improvement from baseline was observed at week 8 in Dermatology Life Quality Index score, visual analog scale score, erythrocyte sedimentation rate, and C-reactive protein compared with placebo. Patients in the placebo group treated with IFX after week 8 (crossover) responded similarly to the original IFX group. Many patients withdrew during the observational phase to continue anti–tumor necrosis factor-alfa therapy. No unexpected serious adverse events were observed.

      Limitations

      Results are representative of a single center, patients were treated by a single physician, some patients did not return after their last infusion, and the HS Severity Index requires validation.

      Conclusions

      This clinical study represents the first formal assessment of IFX for treatment of moderate to severe HS. IFX was well tolerated, no unexpected safety issues were identified, and improvements in pain intensity, disease severity, and quality of life were demonstrated with concomitant reduction in clinical markers of inflammation.

      Key words

      Abbreviations used:

      AE ( adverse event), CD ( Crohn disease), CRP ( C-reactive protein), DLQI ( Dermatology Life Quality Index), ESR ( erythrocyte sedimentation rate), HS ( hidradenitis suppurativa), HSSI ( Hidradenitis Suppurativa Severity Index), IFX ( infliximab), PGA ( Physician Global Assessment), placeboIFX ( placebo patients after crossover), TNF ( tumor necrosis factor), VAS ( visual analog scale)
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Poli F.
        • Jemec G.B.E.
        • Revuz J.
        Clinical presentation.
        in: Jemec G.B.E. Revuz J. Leyden J.J. Hidradenitis suppurativa. Springer-Verlag, Heidelberg (Germany)2006: 11-24
      1. Jemec G.B.E. Revuz J. Leyden J.J. Hidradenitis suppurativa. Springer-Verlag, Heidelberg (Germany)2006
        • Krbec A.C.
        Current understanding and management of hidradenitis suppurativa.
        J Am Acad Nurse Pract. 2007; 19: 228-234
        • Gao M.
        • Wang P.G.
        • Cui Y.
        • Yang S.
        • Zhang Y.H.
        • Lin D.
        • et al.
        Inversa acne (hidradenitis suppurativa): a case report and identification of the locus at chromosome 1p21.1-1q25.3.
        J Invest Dermatol. 2006; 126: 1302-1306
        • Von Der Werth J.M.
        • Williams H.C.
        • Raeburn J.A.
        The clinical genetics of hidradenitis suppurativa revisited.
        Br J Dermatol. 2000; 142: 947-953
        • Fitzsimmons J.S.
        • Guilbert P.R.
        • Fitzsimmons E.M.
        Evidence of genetic factors in hidradenitis suppurativa.
        Br J Dermatol. 1985; 113: 1-8
        • Jemec G.B.
        • Thomsen B.M.
        • Hansen U.
        The homogeneity of hidradenitis suppurativa lesions: a histological study of intra-individual variation.
        APMIS. 1997; 105: 378-383
        • Jansen I.
        • Altmeyer P.
        • Piewig G.
        Acne inversa (alias hidradenitis suppurativa).
        J Eur Acad Dermatol Venereol. 2001; 15: 532-540
        • Oprica C.
        • Nord C.E.
        Bacteriology of hidradenitis suppurativa.
        in: Jemec G.B.E. Revuz J. Leyden J.J. Hidradenitis suppurativa. Springer-Verlag, Heidelberg (Germany)2006: 86-94
        • Boer J.
        • Weltevreden E.F.
        Hidradenitis suppurativa or acne inversa: a clinicopathological study of early lesions.
        Br J Dermatol. 1996; 135: 721-725
        • Wolkenstein P.
        • Loundou A.
        • Barrau K.
        • Auquier P.
        • Revuz J.
        Quality of life impairment in hidradenitis suppurativa: a study of 61 cases.
        J Am Acad Dermatol. 2007; 56: 621-623
        • von der Werth J.M.
        • Jemec G.B.
        Morbidity in patients with hidradenitis suppurativa.
        Br J Dermatol. 2001; 144: 809-813
        • Harrison B.J.
        • Mudge M.
        • Hughes L.E.
        The prevalence of hidradenitis suppurativa in South Wales.
        in: Marks R. Plewig G. Acne and related disorders. Martin Dunitz Ltd, London1988 (pp. 365-66)
        • Jemec G.B.
        • Heidenheim M.
        • Nielsen N.H.
        The prevalence of hidradenitis suppurativa and its potential precursor lesions.
        J Am Acad Dermatol. 1996; 35: 191-194
        • Jemec G.B.
        Medical treatment of hidradenitis suppurativa.
        Expert Opin Pharmacother. 2004; 5: 1767-1770
        • Slade D.E.
        • Powell B.W.
        • Mortimer P.S.
        Hidradenitis suppurativa: pathogenesis and management.
        Br J Plast Surg. 2003; 56: 451-461
        • Kagan R.J.
        • Yakuboff K.P.
        • Warner P.
        • Warden G.D.
        Surgical treatment of hidradenitis suppurativa: a 10-year experience.
        Surgery. 2005; 138: 734-741
        • Rompel R.
        • Petres J.
        Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa.
        Dermatol Surg. 2000; 26: 638-643
        • Keating G.M.
        • Perry C.M.
        Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
        BioDrugs. 2002; 16: 111-148
        • Gottlieb A.B.
        • Evans R.
        • Li S.
        • Dooley L.T.
        • Guzzo C.A.
        • Baker D.
        • et al.
        Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.
        J Am Acad Dermatol. 2004; 51: 534-542
        • Martinez F.
        • Nos P.
        • Benlloch S.
        • Ponce J.
        Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab.
        Inflamm Bowel Dis. 2001; 7: 323-326
        • Katsanos K.H.
        • Christodoulou D.K.
        • Tsianos E.V.
        Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patient.
        Am J Gastroenterol. 2002; 97: 2155-2156
        • Gupta A.K.
        • Skinner A.R.
        A review of the use of infliximab to manage cutaneous dermatoses.
        J Cutan Med Surg. 2004; 8: 77-89
        • Sands B.E.
        • Anderson F.H.
        • Bernstein C.N.
        • Chey W.Y.
        • Feagan B.G.
        • Fedorak R.N.
        • et al.
        Infliximab maintenance therapy for fistulizing Crohn's disease.
        N Engl J Med. 2004; 350: 876-885
        • Bhalla R.
        • Sequeira W.
        Arthritis associated with hidradenitis suppurativa.
        Ann Rheum Dis. 1994; 53: 64-66
        • Rosi Y.L.
        • Lowe L.
        • Kang S.
        Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease.
        J Dermatolog Treat. 2005; 16: 58-61
        • Roussomoustakaki M.
        • Dimoulios P.
        • Chatzicostas C.
        • Kritikos H.D.
        • Romanos J.
        • Panayiotides J.G.
        • et al.
        Hidradenitis suppurativa associated with Crohn's disease and spondyloarthropathy: response to anti-TNF therapy.
        J Gastroenterol. 2003; 38: 1000-1004
        • Mekkes J.R.
        • Bos J.D.
        Long-term efficacy of a single course of infliximab in hidradenitis suppurativa.
        Br J Dermatol. 2008; 158: 370-374
        • Kristensen M.
        • Chu C.Q.
        • Eedy D.J.
        • Feldmann M.
        • Brennan F.M.
        • Breathnach S.M.
        Localization of tumor necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor.
        Clin Exp Immunol. 1993; 94: 354-362
        • Hansen R.A.
        • Gartlehner G.
        • Powell G.E.
        • Sandler R.S.
        Serious adverse events with infliximab: analysis of spontaneously reported adverse events.
        Clin Gastroenterol Hepatol. 2007; 5: 729-735
        • Adams D.R.
        • Gordon K.B.
        • Devenyi A.G.
        • Ioffreda M.D.
        Severe hidradenitis suppurativa treated with infliximab infusion.
        Arch Dermatol. 2003; 139: 1540-1542
        • Sullivan T.P.
        • Welsh E.
        • Kerdel F.A.
        • Burdick A.E.
        • Kirsner R.S.
        Infliximab for hidradenitis suppurativa.
        Br J Dermatol. 2003; 149: 1046-1049
        • Lebwohl B.
        • Sapadin A.N.
        Infliximab for the treatment of hidradenitis suppurativa.
        J Am Acad Dermatol. 2003; 49: S275-S276
        • Fardet L.
        • Dupuy A.
        • Kerob D.
        • Levy A.
        • Allez M.
        • Begon E.
        • et al.
        Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients.
        J Am Acad Dermatol. 2007; 56: 624-628
        • Moschella S.L.
        Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases.
        Int J Dermatol. 2007; 46: 1287-1291
      2. Drucker AM, Winkelman WJ, Walsh S, Shear NH. Long term experience with infliximab in hidradenitis suppurativa and pyroderma gangrenosum: a case series of 9 patients. Presented orally at: Canadian Dermatology Association 83rd Annual Conference, June 2008, Montreal.

        • Reich K.
        • Nestle F.O.
        • Papp K.
        • Ortonne J.P.
        • Evans R.
        • Guzzo C.
        • et al.
        Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicenter, double-blind trial.
        Lancet. 2005; 366: 1367-1374
        • Menter A.
        • Feldman S.R.
        • Weinstein G.D.
        • Papp K.
        • Evans R.
        • Guzzo C.
        • et al.
        A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
        J Am Acad Dermatol. 2007; 56: e1-e15
        • Stern R.
        • Wolfe F.
        Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis.
        J Rheumatol. 2004; 31: 1538-1545
        • Finlay A.Y.
        • Khan G.K.
        Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use.
        Clin Exp Dermatol. 1994; 19: 210-216
        • Giamarellos-Bourboulis E.J.
        • Antonopoulou A.
        • Petropoulou C.
        • Mouktaroudi M.
        • Spyridaki E.
        • Baziaka F.
        • et al.
        Altered innate and adaptive immune responses in patients with hidradenitis suppurativa.
        Br J Dermatol. 2007; 156: 51-56
        • Price D.D.
        • McGrath P.A.
        • Rafii A.
        • Buckingham B.
        The validation of visual analogue scales as ratio scale measures for chronic and experimental pain.
        Pain. 1983; 17: 45-56
        • Fernandez-Vozmediano J.M.
        • Armario-Hita J.C.
        Infliximab for the treatment of hidradenitis suppurativa.
        Dermatology. 2007; 215: 41-44
        • Revuz J.
        Modifications to the Sartorius score and instructions for evaluating the severity of suppurative hidradenitis.
        Ann Dermatol Venereol. 2007; 134: 173-174
        • Sartorius K.
        • Lapins J.
        • Emtestam L.
        • Jemec G.B.
        Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa.
        Br J Dermatol. 2003; 149: 211-213
        • Giamarellos-Bourboulis E.J.
        • Pelekanou E.
        • Antonopoulou A.
        • Petropoulou H.
        • Baziaka F.
        • Karagianni V.
        • et al.
        An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa.
        Br J Dermatol. 2008; 158: 567-572
        • Jemec G.B.
        • Wendelboe P.
        Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa.
        J Am Acad Dermatol. 1998; 39: 971-974
        • Mortimer P.S.
        • Dawber R.P.
        • Gales M.A.
        • Moore R.A.
        Mediation of hidradenitis suppurativa by androgens.
        Br Med J (Clin Res Ed). 1986; 292: 245-248
        • Mortimer P.S.
        • Lunniss P.J.
        Hidradenitis suppurativa.
        J R Soc Med. 2000; 93: 420-422
        • Revuz J.
        The role of surgery in the treatment of hidradenitis suppurativa.
        Ann Dermatol Venereol. 2008; 135: 349-350
        • Buckley D.A.
        • Rogers S.
        Cyclosporin-responsive hidradenitis suppurativa.
        J R Soc Med. 1995; 88 (289-90)
        • Jemec G.B.
        Methotrexate is of limited value in the treatment of hidradenitis suppurativa.
        Clin Exp Dermatol. 2002; 27: 528-529
        • Cusack C.
        • Buckley C.
        Etanercept: effective in the management of hidradenitis suppurativa.
        Br J Dermatol. 2006; 154: 726-729
        • Moul D.K.
        • Korman N.J.
        The cutting edge: severe hidradenitis suppurativa treated with adalimumab.
        Arch Dermatol. 2006; 142: 1110-1112
        • Hanauer S.B.
        • Feagan B.G.
        • Lichtenstein G.R.
        • Mayer L.F.
        • Schreiber S.
        • Colombel J.F.
        • et al.
        Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial.
        Lancet. 2002; 359: 1541-1549
        • Baert F.
        • Noman M.
        • Vermeire S.
        • Van Assche G.
        • D'Haens G.
        • Carbonez A.
        • et al.
        Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
        N Engl J Med. 2003; 348: 601-608

      Linked Article

      • Rifampicin and clindamycin for hidradenitis
        Journal of the American Academy of DermatologyVol. 64Issue 4
        • In Brief
          To the Editor: We read with interest the recent article by Grant et al1 on infliximab therapy for patients with moderate to severe hidradenitis suppurativa (HS) in which the authors state that “currently available medical treatments are minimally effective in cases of moderate to severe HS”.
        • Full-Text
        • PDF